ArticleAlimentary pharmacology & therapeutics2026
Serum Villin-1-A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundGut barrier dysfunction contributes to acute decompensation (AD) of cirrhosis progression but, it is not acknowledged in severity or prognostic scores due to a lack of appropriate assessment tools.
aimWe investigated serum villin-1 (VIL1), an epithelial brush-border associated actin-binding protein, as a non-invasive marker for gut injury and prognosis in AD cirrhosis.
methodsSerum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute-on-chronic liver failure [ACLF]) from MICROB-PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies (n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.
resultsCompared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90-day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut-off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF-C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90-day mortality (HR: 2.52, CI: 1.648-3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.
conclusionSerum VIL1 is a non-invasive indicator of gut barrier damage and short-term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.